- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00028873
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
An EORTC-IDBBC/ECSG Phase II Study Evaluating The Role Of The Multi-Drug Resistance (MDR) Reversor, R101933, In Patients With Taxane Refractory Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining R101933 with paclitaxel or docetaxel may reduce resistance to the drug and allow the tumor cells to be killed.
PURPOSE: Phase II trial to study the effectiveness of combining R101933 with either paclitaxel or docetaxel in treating patients who have metastatic breast cancer that has not responded to previous chemotherapy.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
- Determine the activity of R101933 in combination with paclitaxel or docetaxel in terms of response to treatment and level of clinical benefit in patients with taxane-refractory metastatic breast cancer.
- Determine the safety of this regimen in these patients.
- Determine the acute side effects in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive R101933 IV over 1 hour immediately followed by paclitaxel IV over 3 hours or docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity. Patients who have no disease progression after 7 courses may continue with treatment at the investigator's discretion.
Patients are followed every 6 weeks until disease progression.
PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Brussels, Belgien, B-1000
- Institut Jules Bordet
-
-
-
-
-
Nantes-Saint Herblain, Frankreich, 44805
- CRLCC Nantes - Atlantique
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
- Histologically confirmed metastatic breast cancer
- Received at least 2 prior courses of paclitaxel-based chemotherapy at doses between 175-200 mg/m^2 (given over 3 hours every 3 weeks) or docetaxel-based chemotherapy at doses between 75-100 mg/m^2 (given over 1 hour every 3 weeks) as most recent anticancer therapy
Evidence of disease resistance
- Progressive disease as best response OR
- Transient response or disease stabilization followed by progression during taxane-based treatment
- Disease progression on a combination of a taxane and another cytotoxic agent allowed
Unidimensionally measurable disease
- At least 1 target lesion that clearly progressed or developed during prior taxane therapy
- Lesions stable or responsive to prior taxane therapy are not considered target lesions
- Lesions that have been irradiated within the past 3 months are not considered target lesions unless they have clearly progressed or appeared since radiotherapy
- No bone metastases as only site of measurable disease
- No rapidly progressive visceral metastases
- No symptomatic CNS metastases
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Sex:
- Not specified
Menopausal status:
- Not specified
Performance status:
- WHO 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- Transaminases no greater than 2.5 times ULN (5 times ULN if liver metastases present)
Renal:
- Creatinine no greater than 1.5 times ULN
- Calcium normal
Cardiovascular:
- LVEF normal by echocardiogram (ECG) or MUGA scan
- QTc less than 450 sec on baseline ECG
- No prior clinically significant arrhythmias requiring treatment
- No cardiac infarction
- No atrial ventricular enlargement or hypertrophy
Other:
- No prior toxicity to paclitaxel that would preclude study dose and schedule
- Sodium, potassium, chloride, and bicarbonate normal
- No pre-existing neuropathy greater than grade 2
- No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix, contralateral breast cancer, or nonmelanoma skin cancer or cancer that has been in remission for more than 5 years
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No concurrent anticancer biologic agents
Chemotherapy:
- See Disease Characteristics
- No more than 8 weeks since last course of prior taxane-based chemotherapy
- No more than 2 prior chemotherapy regimens for metastatic breast cancer
- No other concurrent anticancer chemotherapy
Endocrine therapy:
- No concurrent anticancer hormonal therapy
Radiotherapy:
- See Disease Characteristics
- No concurrent radiotherapy
Surgery:
- Not specified
Other:
- No prior multi-drug resistance inhibitor
- No new anticancer therapy initiation since last course of prior taxane-based chemotherapy
- No concurrent angiotensin converting enzyme inhibitor and/or drugs that may prolong the QTc interval
- No other concurrent anticancer therapy
- Concurrent bisphosphonates for treatment and prevention of bony metastases allowed provided drugs were initiated prior to study (treatment of hypercalcemia due to malignancy allowed regardless of time of initiation)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Pierre Fumoleau, MD, PhD, Centre Georges Francois Leclerc
- Studienstuhl: Bernardo L. Rapoport, MD, MMed(IntMed), Medical Oncology Centre of Rosebank
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- EORTC-10003-16004
- EORTC-16004
- ECSG-EORTC-16004
- IDBBC-10003
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur Docetaxel
-
Optimal Health ResearchAbgeschlossenBrustkrebs | Lungenkrebs | ProstatakrebsVereinigte Staaten
-
Tianjin Medical University Cancer Institute and...Rekrutierung
-
Zhuhai Beihai Biotech Co., LtdAbgeschlossenSolide Tumore | Bioäquivalenz | DocetaxelIndien
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaAbgeschlossenNicht-kleinzelliger Lungenkrebs (NSCLC)China
-
Nereus Pharmaceuticals, Inc.AbgeschlossenKrebsVereinigte Staaten, Australien, Indien, Chile, Brasilien, Argentinien
-
SanofiAbgeschlossenLungentumorenFrankreich, Niederlande, Spanien, Truthahn, Belgien, Finnland, Italien, Vereinigtes Königreich
-
Fudan UniversityNoch keine RekrutierungFortgeschrittener nicht-kleinzelliger Lungenkrebs
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRekrutierungKastrationsresistenter ProstatakrebsAustralien
-
Hunan Cancer HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.; Hunan Provincial People's...UnbekanntNicht-kleinzelligem LungenkrebsChina
-
Seoul National University HospitalClinical Research Center for Solid Tumor, KoreaBeendetKopf-Hals-PlattenepithelkarzinomKorea, Republik von